Arcutis (ARQT) Earnings Call Signals Scaled Growth

Arcutis Biotherapeutics Inc ((ARQT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Arcutis Biotherapeutics Inc. struck an optimistic tone on its latest earnings call, pairing rapid revenue expansion and record quarterly results with a clear path toward sustained profitability. Management emphasized accelerating prescription momentum, expanding labels, and strong cash generation, while openly flagging higher near‑term spending and access constraints in certain payer channels.

Explosive Full-Year Revenue Growth

Net product revenues for 2025 surged to $372.1 million, a 123% jump versus 2024 as demand for ZORYVE broadened across approved indications. Management framed this growth as evidence that its topical dermatology strategy is scaling, with a larger patient base and greater prescriber confidence driving repeat use.

Record Fourth Quarter Caps Breakout Year

Fourth quarter 2025 net product revenues reached a record $127.5 million, up 84% year over year and 29% sequentially from Q3. The quarterly step‑up was fueled by a 19% increase in prescription volume, underscoring strong underlying demand rather than one‑off price or inventory effects.

Prescription Momentum and Market Share Gains

Total prescription volume roughly doubled in 2025, with the 4‑week rolling average approaching 22,000 weekly scripts. ZORYVE now commands about 45% share of branded nonsteroidal topical prescriptions, positioning it as a leading nonsteroid option in key dermatology markets.

Regulatory Wins and Label Expansion

In 2025, the company secured FDA approvals for ZORYVE foam 0.3% in scalp and body psoriasis for patients 12 and older and for ZORYVE cream 0.05% in atopic dermatitis in children aged 2 to 5. Arcutis has also filed a supplemental application for ZORYVE cream 0.3% in psoriasis for ages 2 to 5, with a regulatory decision expected in mid‑2026.

Encouraging Pediatric Phase II Data

Pediatric development advanced with positive Phase II results from the INTEGUMENT‑INFANT trial in infants 3 to 24 months old with atopic dermatitis. By week 4, 58% of patients achieved EASI‑75 and around one‑third reached that endpoint by week 2, with no serious treatment‑emergent safety issues and only one discontinuation reported.

Pipeline Expansion and New Clinical Programs

Arcutis broadened its pipeline by initiating Phase II proof‑of‑concept studies of ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, two difficult‑to‑treat inflammatory skin diseases. The company also filed an investigational application for ARQ‑234, a novel biologic, and expects to begin Phase I dosing shortly, signaling a move beyond topicals.

Profitability Inflection and Strong Cash Position

The business showed clear operating leverage, with net loss narrowing to $16.1 million in 2025 from $140.0 million in 2024. In Q4, Arcutis generated $17.4 million of net income and $26.2 million in positive operating cash flow, finishing the year with $221.3 million in cash and marketable securities.

Commercial Footprint and Access Improvements

The dermatology sales force grew about 20% to roughly 160 representatives, and Arcutis launched a 30‑person primary care and pediatrics pilot team. On the access side, ZORYVE is now on more than 80% of commercial formularies and over half of Medicaid lives with single‑step edits, while on some formularies it is the only branded nonsteroidal topical option.

Raised 2026 Revenue Guidance

Strong Q4 performance prompted management to lift 2026 net product revenue guidance to a range of $480 million to $495 million, up $25 million at each end of the prior outlook. The company also reiterated expectations to remain cash‑flow positive on a quarterly basis through 2026, even as it invests in expanded sales coverage.

Rising Operating Expenses from Growth Investments

Selling, general, and administrative expenses climbed to $79.0 million in Q4, up 37% year over year, and $274.6 million for full‑year 2025, a 20% increase as commercialization scaled. Looking ahead, management expects research and development spending to rise in 2026 as new clinical programs, including ARQ‑234 and foam studies, move forward.

Seasonality and Gross-to-Net Headwinds

Gross‑to‑net discounts remain in the 50% range and are expected to tick into the high‑50s in Q1 due to deductible resets and heavier co‑pay support. Arcutis also flagged a more pronounced seasonal step down from Q4 to Q1 in early 2026, partly reflecting a modest 2% channel inventory build in Q4 that should unwind.

Medicare Part D Access Still a Constraint

While ZORYVE has made inroads into Medicare Part D, coverage extends to only about one‑third of plans and largely on non‑preferred tiers with higher patient cost sharing. Management cautioned that broader Part D penetration may not materialize until 2027, potentially tempering uptake in the Medicare population in the near term.

Shifting Revenue Mix and Available Leverage

Other revenue fell to $4.0 million in 2025 from $30.0 million a year earlier, reflecting the absence of a prior $25.0 million upfront licensing payment and underscoring the growing reliance on product sales. The company carries $108 million of debt but also holds an option to draw an additional $100 million through mid‑2026, providing balance‑sheet flexibility if needed.

Execution Risk Around Commercial Expansion Timing

Management believes the enlarged dermatology sales force and the new primary care and pediatric pilot will be accretive, but most benefits should emerge in the second half of 2026. Investors may see higher spending in the nearer term without a proportionate immediate revenue lift as these initiatives ramp.

Guidance and Outlook

Looking ahead, Arcutis is guiding to 2026 net product revenues between $480 million and $495 million, supported by current momentum, expanded labels, and a deeper commercial footprint. The company expects to remain cash‑flow positive each quarter, maintain gross‑to‑net in the 50s despite Q1 pressure, and fund its sales‑force expansion and pipeline from its $221.3 million cash balance plus available debt capacity.

Arcutis’ latest call painted a picture of a dermatology specialist rapidly scaling into a more mature commercial business while carefully managing risk. With ZORYVE gaining share, profitability improving, and guidance moving higher, investors now face a classic growth trade‑off: near‑term expense and access noise versus the potential for sustained revenue compounding in the back half of the decade.